N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity.
about
An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A)Clinical oxidative stress during leprosy multidrug therapy: impact of dapsone oxidationIncreased constitutive c-Jun N-terminal kinase signaling in mice lacking glutathione S-transferase PiSummary of information on human CYP enzymes: human P450 metabolism data.Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.An evaluation of dapsone gel 5% in the treatment of acne vulgaris.How useful is the "cocktail approach" for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?Systematic review: ursodeoxycholic acid--adverse effects and drug interactions.Drug bioactivation, covalent binding to target proteins and toxicity relevance.Pharmacokinetic considerations in clinical toxicology: clinical applications.Effects of genetic variation at the CYP2C19/CYP2C9 locus on pharmacokinetics of chlorcycloguanil in adult Gambians.Systemic use of non-biologic agents in orofacial diseases: other immunomodulatory agents.Isatin-benzoazine molecular hybrids as potential antiproliferative agents: synthesis and in vitro pharmacological profilingDapsone and azole interactions: A clinical perspective.Severe dapsone hypersensitivity syndrome in a child.[Dapsone-induced agranulocytosis. The role of xenobiotic-metabolizing enzymes demonstrated by a case report].Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjectsA convenient five-drug cocktail for the assessment of major drug metabolizing enzymes: a pilot study.Alosetron repeat dose pharmacokinetics, effects on enzyme activities, and influence of demographic factors.Effect of age and postoperative time on cytochrome p450 enzyme activity following liver transplantation.Satraplatin activation by haemoglobin, cytochrome C and liver microsomes in vitro.Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.Determination of a 'GW cocktail' of cytochrome P450 probe substrates and their metabolites in plasma and urine using automated solid phase extraction and fast gradient liquid chromatography tandem mass spectrometry.Probable warfarin and dapsone interaction.Structure activity relationship study on the peptide hormone preptin, a novel bone-anabolic agent for the treatment of osteoporosis.
P2860
Q28365904-0DD84BE3-1DB8-4508-AE77-C5ADE2F12970Q28538986-969552AF-D8EC-4424-B1C9-50FD50DBF5B1Q28589006-B1A811F8-C4A9-4FC2-A1B4-FD3B0DDD8CEDQ32103802-5C7E67A3-7EB8-463D-8900-19183481FE30Q33858325-F469E0EE-AE22-4611-91C9-978285C83F23Q34985540-C4DE8681-4EBE-40EA-A71E-96B97E821D22Q35149421-0A107286-06FD-41CF-9C7D-F1327285E890Q35583064-2D93AB9D-3DA6-4BDE-BD88-7018A6DADEB4Q36061821-70F205D7-174C-4822-B08B-6666239ED680Q36964648-C2B47263-9AA7-49B4-8272-3D4E6B3183EAQ37409135-FD954170-8752-4D97-A8CF-FE615F48D2CCQ38136748-B4361666-7FA8-463B-BD30-B63F0E0AD13BQ38694005-FD1E3A66-D060-4F0B-BD74-90F027BB5848Q39450909-AACE1883-BFBB-4767-980C-B8CC3235B3D2Q40243010-8132AB66-9DF9-4EF3-94C0-45308737226CQ40504499-50750E01-3B03-462D-8F93-AE5F72DF444BQ41906399-FD2A2948-CF6E-4CE7-B1E5-B2C394D98FB8Q42284131-B6B36A44-F56D-4DA2-B084-C7A7874445ACQ44963267-51F2E93E-375B-4126-959E-CAE0FD7ABFBFQ46038612-2F2EEF94-2747-4FB4-9241-EFD6719FD0A3Q46711988-866D4B99-9027-4812-8B94-D7DD67F16B2FQ48610657-B3E713B4-2018-4FC7-B89E-BB796EE29540Q51432740-A4533605-CCF6-4141-A5BB-0D11AA783A90Q53146777-254F79A5-6DA3-48D0-B1DE-8B5D8F444158Q53755539-7FF75042-DBFB-4F38-B270-8066BA1F169F
P2860
N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity.
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
N-Hydroxylation of dapsone by ...... r inhibition of haemotoxicity.
@en
N-Hydroxylation of dapsone by ...... r inhibition of haemotoxicity.
@nl
type
label
N-Hydroxylation of dapsone by ...... r inhibition of haemotoxicity.
@en
N-Hydroxylation of dapsone by ...... r inhibition of haemotoxicity.
@nl
prefLabel
N-Hydroxylation of dapsone by ...... r inhibition of haemotoxicity.
@en
N-Hydroxylation of dapsone by ...... r inhibition of haemotoxicity.
@nl
P2093
P2860
P1476
N-Hydroxylation of dapsone by ...... r inhibition of haemotoxicity.
@en
P2093
P2860
P304
P356
10.1111/J.1365-2125.1995.TB05797.X
P407
P577
1995-12-01T00:00:00Z